NATCO's Bulk Drug facility at Sanathnagar, India, amply supported by a world-class, state of the art, research lab, is capable of manufacturing in small quantities, a variety of bulk drug and intermediates which comply to International standards. This facility is extremely efficient in handling complex reactions.
The bulk drug facility at Mekaguda, India commenced commercial production in 1994. A TGA (Australia) approved, state-of-the-science multipurpose manufacturing facility for the API's (active pharmaceutical ingredients) with self-supportive R&D, Quality Control and experienced staff operate three manufacturing blocks, two pilot installations and offer Maintenance, Warehousing and other management services within the modern facility.
NATCO has built up a large infrastructure to undertake manufacturing in bulk actives and intermediates.With a combined capacity of 370 KL, from 75 stainless steel and 20 glass lined reactors, these facilities are well equipped with modern line up of instrumentation, utilities, clean rooms and environment management systems required to output finished products of a very high quality. An efficient and modern Quality Assurance system ensures compliance with the highest quality norms prevalent.
This infrastructure has enabled NATCO emerge very strong, in areas of custom syntheses and process chemistry. NATCO has significant expertise in:
- Benzimidazole Chemistry
- Pyridine Chemistry (On Pyridine) Grignard Chemistry
- Cynations
- Carroll Rearrangement
- Halex Reactions
- Sulfoxidations
- Metal Hydride Reductions
- Acetyllenic Chemistry
- Friedel Crafts Reactions
- Chloromethylations (Blanc)
- Broche - Drechsel Carbazole Crystallization
- Darzens - Glycidic Esser Condensation
- Vilsmeier - Haack Reaction
- Reductive - Aminations
- Fisher Indole Synthesis
- Hoffmann Reaction
- Oxidations
- Precious metal handling
- Handling of Phosphorous Compounds
- Reductions / preparations of PhenylHydrazines.
- Japp - Klingemann Reaction.
- Resolutions